These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36532902)

  • 21. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.
    Guan Y; Puenpatom A; Johnson MG; Zhang Y; Zhao Y; Surber J; Weinberg A; Brotons C; Kozlov R; Lopez R; Coetzee K; Santiaguel J; Du J; Williams-Diaz A; Brown M; Paschke A; De Anda C; Norquist JM
    Clin Infect Dis; 2023 Nov; 77(11):1521-1530. PubMed ID: 37466374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Why Molnupiravir Fails in Hospitalized Patients.
    Brown AN; Lang Y; Zhou J; Franco EJ; Hanrahan KC; Bulitta JB; Drusano GL
    mBio; 2022 Dec; 13(6):e0291622. PubMed ID: 36374076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
    Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
    Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial.
    Strizki JM; Grobler JA; Murgolo N; Fridman A; Johnson MG; Du J; Carmelitano P; Brown ML; Paschke A; De Anda C
    Infect Dis Ther; 2023 Dec; 12(12):2725-2743. PubMed ID: 37995070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
    Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
    Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
    Aricò E; Castiello L; Bracci L; Urbani F; Lombardo F; Bacigalupo I; Ancidoni A; Vanacore N; Falcione A; Reggiani C; Dutti GM; Maglie MG; Papa O; Bartoletti PL; Ozzella G; Bevilacqua N; Nicastri E; Belardelli F; Sconocchia G
    Trials; 2021 Sep; 22(1):584. PubMed ID: 34479601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molnupiravir and Its Antiviral Activity Against COVID-19.
    Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
    Front Immunol; 2022; 13():855496. PubMed ID: 35444647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molnupiravir in COVID-19: A systematic review of literature.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study.
    Gentile I; Scotto R; Schiano Moriello N; Pinchera B; Villari R; Trucillo E; Ametrano L; Fusco L; Castaldo G; Buonomo AR; Federico Ii Covid Team
    Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
    Khoo SH; Fitzgerald R; Fletcher T; Ewings S; Jaki T; Lyon R; Downs N; Walker L; Tansley-Hancock O; Greenhalf W; Woods C; Reynolds H; Marwood E; Mozgunov P; Adams E; Bullock K; Holman W; Bula MD; Gibney JL; Saunders G; Corkhill A; Hale C; Thorne K; Chiong J; Condie S; Pertinez H; Painter W; Wrixon E; Johnson L; Yeats S; Mallard K; Radford M; Fines K; Shaw V; Owen A; Lalloo DG; Jacobs M; Griffiths G
    J Antimicrob Chemother; 2021 Nov; 76(12):3286-3295. PubMed ID: 34450619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience.
    De Vito A; Colpani A; Bitti A; Zauli B; Meloni MC; Fois M; Denti L; Bacciu S; Marcia C; Maida I; Babudieri S; Madeddu G
    J Med Virol; 2022 Nov; 94(11):5582-5588. PubMed ID: 35855627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
    González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
    Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19).
    Urwyler P; Charitos P; Moser S; Heijnen IAFM; Trendelenburg M; Thoma R; Sumer J; Camacho-Ortiz A; Bacci MR; Huber LC; Stüssi-Helbling M; Albrich WC; Sendi P; Osthoff M
    Trials; 2021 Jan; 22(1):1. PubMed ID: 33397449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molnupiravir Outpatient Treatment for Adults with COVID-19 in a Real-World Setting-A Single Center Experience.
    Czarnecka K; Czarnecka P; Tronina O; Durlik M
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial.
    Manomaipiboon A; Pholtawornkulchai K; Poopipatpab S; Suraamornkul S; Maneerit J; Ruksakul W; Phumisantiphong U; Trakarnvanich T
    Trials; 2022 Aug; 23(1):714. PubMed ID: 36028897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
    Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized open-label trial to evaluate the efficacy and safety of triple therapy with aspirin, atorvastatin, and nicorandil in hospitalised patients with SARS Cov-2 infection: A structured summary of a study protocol for a randomized controlled trial.
    Sharma A; Sharma C; Raina S; Singh B; Dadhwal DS; Dogra V; Gupta S; Bhandari S; Sood V
    Trials; 2021 Jul; 22(1):451. PubMed ID: 34266452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.